Launch

RSA to Demonstrate Identity Security Innovations Critical to Meeting NIST CSF 2.0 and Eliminating Passwords at RSA Conference 2024

Retrieved on: 
화요일, 5월 7, 2024

RSA, the security-first identity leader, announced new product enhancements at RSA Conference 2024 to help organizations meet the National Institute of Standards and Technology’s Cybersecurity Framework 2.0 ( NIST CSF 2.0 ) advanced security standards and eliminate passwords.

Key Points: 
  • RSA, the security-first identity leader, announced new product enhancements at RSA Conference 2024 to help organizations meet the National Institute of Standards and Technology’s Cybersecurity Framework 2.0 ( NIST CSF 2.0 ) advanced security standards and eliminate passwords.
  • Specifically, CSF 2.0 addresses a threat landscape now dominated by identity-driven threats and makes extensive recommendations to counteract them.
  • “NIST CSF 2.0 makes it clear that, no matter the size and no matter the sector, every organization is only as secure as its identities,” said RSA CEO Rohit Ghai.
  • “The tech industry shapes identity, and identity shapes the world,” said RSA CMO Laura Marx.

Rocket Lab Announces First Quarter 2024 Financial Results Reflecting Year-on-Year Revenue Growth of 69%, Sequential Quarterly Growth of 55%, and Continued Growth in Q2 2024

Retrieved on: 
월요일, 5월 6, 2024

Meaningful progress made on the production and testing of two Rocket Lab spacecraft for NASA’s ESCAPADE mission to Mars.

Key Points: 
  • Meaningful progress made on the production and testing of two Rocket Lab spacecraft for NASA’s ESCAPADE mission to Mars.
  • For the second quarter of 2024, Rocket Lab expects:
    Revenue between $105 million and $110 million.
  • ET) today to discuss these business highlights and financial results for our first quarter, to provide our outlook for the second quarter, and other updates.
  • The live webcast and a replay of the webcast will be available on Rocket Lab’s Investor Relations website: https://investors.rocketlabusa.com/events-and-presentations/events .

NASA Sets Coverage for Boeing Starliner's First Crewed Launch, Docking

Retrieved on: 
월요일, 4월 29, 2024

1:30 p.m. – Virtual news conference at Kennedy with the flight test astronauts:

Key Points: 
  • 1:30 p.m. – Virtual news conference at Kennedy with the flight test astronauts:
    Coverage of the virtual news conference will stream live on NASA+ , NASA Television, the NASA app , YouTube , and the agency's website .
  • 6:30 p.m. – Launch coverage begins on NASA+ , NASA Television, the NASA app , YouTube , and the agency's website .
  • NASA+ will resume coverage and NASA Television's media channel will break from in-orbit coverage to carry the postlaunch news conference.
  • Once the postlaunch news conference is complete, NASA+ coverage will end, and mission coverage will continue on both NASA channels.

Novartis’ Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Retrieved on: 
화요일, 4월 16, 2024

Approximately five months post-approval, over one-third of US rheumatologists (n=104) report prescribing the IV formulation for their patients with PsA.

Key Points: 
  • Approximately five months post-approval, over one-third of US rheumatologists (n=104) report prescribing the IV formulation for their patients with PsA.
  • Furthermore, the vast majority feel the new formulation of Novartis’ IL-17-inhibitor brings some degree of advance over existing PsA treatments.
  • Receptivity to the IV formulation has also resulted in a greater affinity for the Cosentyx brand overall, specifically in comparison to long-standing IL-17 rival, Eli Lilly’s Taltz.
  • Launch tracking of Bimzelx will commence following approval and will continue for the first eighteen months of availability through the Launch Dynamix™ service.

Tineco Announces the Launch of the Floor One S7 FlashDry, Revolutionizing Cleaning!

Retrieved on: 
수요일, 4월 24, 2024

Tineco, a specialist in floor care and smart appliances, launches the Tineco Floor One S7 FlashDry, a breakthrough in intelligent cleaning.

Key Points: 
  • Tineco, a specialist in floor care and smart appliances, launches the Tineco Floor One S7 FlashDry, a breakthrough in intelligent cleaning.
  • View the full release here: https://www.businesswire.com/news/home/20240424832533/en/
    Tineco Announces the Launch of the Floor One S7 FlashDry, Revolutionizing Cleaning!
  • (Photo: Business Wire)
    The Tineco Floor One S7 FlashDry is designed to deliver an effortless cleaning experience and impeccable results.
  • The Tineco Floor One S7 FlashDry is available in multiple options, including the Floor One S7 Combo and the Floor One S7 Pro, to meet the specific needs of each household.

PDP Celebrates Fortnite Festival Season 3 With the Launch of the RIFFMASTER Wireless Guitar Controller

Retrieved on: 
화요일, 4월 23, 2024

Leading gaming accessory maker Turtle Beach Corporation (Nasdaq: HEAR), and Performance Designed Products LLC (PDP) today announced the official launch of PDP’s highly-coveted RIFFMASTER wireless guitar controller ($129.99 MSRP).

Key Points: 
  • Leading gaming accessory maker Turtle Beach Corporation (Nasdaq: HEAR), and Performance Designed Products LLC (PDP) today announced the official launch of PDP’s highly-coveted RIFFMASTER wireless guitar controller ($129.99 MSRP).
  • The RIFFMASTER is the first guitar controller designed for today’s rhythm-action gamers and is compatible with Fortnite Festival Pro Lead and Pro Bass song parts in addition to Rock Band™ 4.
  • View the full release here: https://www.businesswire.com/news/home/20240423402701/en/
    PDP Celebrates Fortnite Festival Season 3 with the Launch of the Riffmaster Wireless Guitar Controller (Graphic: Business Wire)
    Pre-orders for the RIFFMASTER sold out just hours following its debut last month.
  • Fans that pre-ordered their RIFFMASTER early are receiving their controllers now during this initial wave of its rolling launch.

NextPlat Reports Consolidated Year-End 2023 Results with Increased Revenues of $37.8 Million, Record Annual Margins of 30% and $26.3 Million in Cash

Retrieved on: 
목요일, 4월 11, 2024

COCONUT GROVE, Fla., April 11, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced the financial results for the fiscal year-ended December 31, 2023 which consolidates the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care").

Key Points: 
  • Results for the full year ended December 2023 reflect e-commerce revenue of approximately $11.0 million and approximately $26.8 million in revenue contributed from the Company's healthcare operations (specifically, Progressive Care whose results are consolidated as of July 1, 2023).
  • Operating expenses for the year ended December 31, 2023, were approximately $34.5 million compared to approximately $9.7 million in the year-ago period.
  • Operating expenses in 2023 also included a non-cash goodwill impairment charge of approximately $13.9 million related to the Progressive Care acquisition.
  • On March 1, 2024, NextPlat launched the exclusive OPKO Healthcare ("OPKO")-branded storefront in China on Alibaba's Tmall Global platform.

US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Retrieved on: 
금요일, 4월 5, 2024

As anticipation builds for the launch of Rezdiffra, Spherix Global Insights recently conducted a pulse survey among gastroenterologists (n=81) to assess prescriber feedback and projected uptake of the brand post-launch.

Key Points: 
  • As anticipation builds for the launch of Rezdiffra, Spherix Global Insights recently conducted a pulse survey among gastroenterologists (n=81) to assess prescriber feedback and projected uptake of the brand post-launch.
  • Furthermore, 70% of gastroenterologists in the March 2024 pulse now report they are at least moderately familiar with Rezdiffra, a significant increase compared to April 2023.
  • When discussing the primary benefits of Rezdiffra, gastroenterologists highlight its distinction as the first indicated product for MASH, alongside its prospective efficacy in improving fibrosis.
  • Furthermore, gastroenterologists indicate that over one-third of MASH patients under their care would be suitable candidates for Rezdiffra, further bolstering the likelihood of swift uptake and utilization.

U.S. Space Force Awards Rocket Lab Launch Contract for Space Test Program (STP)-S30

Retrieved on: 
월요일, 4월 8, 2024

Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”) today announced it has been awarded a $14.49 million task order by the U.S. Space Force (USSF) to launch an Electron mission from Launch Complex 2.

Key Points: 
  • Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”) today announced it has been awarded a $14.49 million task order by the U.S. Space Force (USSF) to launch an Electron mission from Launch Complex 2.
  • The mission, called Space Test Program-30 (STP-S30) falls under the Space Systems Command (SSC) Assured Access to Space organization and is part of Orbital Services Program-4 (OSP-4).
  • View the full release here: https://www.businesswire.com/news/home/20240408470615/en/
    Electron at Launch Complex 2 at the Mid-Atlantic Regional Spaceport within NASA Wallops Flight Facility in Virginia.
  • "Flexible, responsive, and reliable launch is critical to ensuring resilient space capabilities for the nation and we’re proud to deliver it to the Space Force once again with Electron,” said Rocket Lab founder and CEO Peter Beck.

Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market

Retrieved on: 
금요일, 3월 22, 2024

The latest results reveal gastroenterologists (n=73) have been slow to incorporate the newest entrants into their already bustling armamentarium, though project rapid adoption over the course of 2024.

Key Points: 
  • The latest results reveal gastroenterologists (n=73) have been slow to incorporate the newest entrants into their already bustling armamentarium, though project rapid adoption over the course of 2024.
  • In terms of unaided awareness of the newly approved medications, Omvoh had the highest recall rates, followed closely by Velsipity and more distantly by Entyvio SC.
  • Conversely, but as expected, Entyvio SC is the most familiar among the three, followed by Velsipity and then Omvoh.
  • The adoption trends regarding gastroenterologist trial rates, overall market share, and average patient initiations exhibit a consistent pattern.